Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Chronic Heart Failure

Free Subscription Articles published in Eur Heart J Retrieve available abstracts of 271 articles: HTML format

Single Articles

August 2022
1. DACHS TM, Duca F, Rettl R, Binder-Rodriguez C, et al
   Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial.
   Eur Heart J. 2022 Aug 1. pii: 6652608. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. BAUERSACHS J, Olsson KM
   Targeting pulmonary hypertension in patients with heart failure and preserved ejection fraction: rather static than DYNAMIC development?
   Eur Heart J. 2022 Aug 1. pii: 6652609. doi: 10.1093.
   PubMed    
   
   
   July 2022
3. BUTLER J, Anker SD, Lund LH, Coats AJS, et al
   Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial.
   Eur Heart J. 2022 Jul 28. pii: 6651164. doi: 10.1093.
   PubMed     Abstract available
   
   
   
4. PACKER M
   Potassium Binders for Patients With Heart Failure? The Real Enlightenment of the DIAMOND Trial.
   Eur Heart J. 2022 Jul 28. pii: 6651163. doi: 10.1093.
   PubMed    
   
   
   
5. VERGALLO R, Volpe M
   Deciphering a decision support tool (CoDE-HF) to improve the diagnosis of acute heart failure.
   Eur Heart J. 2022 Jul 22. pii: 6648207. doi: 10.1093.
   PubMed    
   
   
   
6. 
   Corrigendum to: Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
   Eur Heart J. 2022 Jul 22. pii: 6649203. doi: 10.1093.
   PubMed    
   
   
   
7. CREA F
   Heart failure: how to optimize guideline-directed medical therapy.
   Eur Heart J. 2022;43:2533-2537.
   PubMed    
   
   
   
8. HADWIGER M, Dagres N, Haug J, Wolf M, et al
   Survival of patients undergoing cardiac resynchronization therapy with or without defibrillator: the RESET-CRT project.
   Eur Heart J. 2022;43:2591-2599.
   PubMed     Abstract available
   
   
   
9. GARG P, Gosling R, Swoboda P, Jones R, et al
   Cardiac magnetic resonance identifies raised left ventricular filling pressure: prognostic implications.
   Eur Heart J. 2022;43:2511-2522.
   PubMed     Abstract available
   
   
   
10. DOEHNER W, Anker SD, Butler J, Zannad F, et al
    Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
    Eur Heart J. 2022 Jul 5. pii: 6631286. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
11. GOYAL P, Kim M, Krishnan U, Mccullough SA, et al
    Post-operative atrial fibrillation and risk of heart failure hospitalization.
    Eur Heart J. 2022 Jun 28. pii: 6617280. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. MIDDELDORP ME, Albert CM
    Post-operative AF and heart failure hospitalizations: what remains hidden in patients undergoing surgery.
    Eur Heart J. 2022 Jun 28. pii: 6617281. doi: 10.1093.
    PubMed    
    
    
    
13. TROMP J, Voors AA
    Heart failure medication: moving from evidence generation to implementation.
    Eur Heart J. 2022 Jun 27. pii: 6618448. doi: 10.1093.
    PubMed    
    
    
    
14. 
    Erratum to: Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
    Eur Heart J. 2022 Jun 18. pii: 6610027. doi: 10.1093.
    PubMed    
    
    
    
15. CREA F
    The complex link among heart failure, atrial fibrillation, and lung diseases, and an update on cardiac transplantation.
    Eur Heart J. 2022;43:2165-2169.
    PubMed    
    
    
    
16. VERMA S, Dhingra NK, Pandey AK, Cosentino F, et al
    Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure.
    Eur Heart J. 2022 Jun 10. pii: 6604931. doi: 10.1093.
    PubMed    
    
    
    
17. FERREIRA JP, Zannad F, Butler J, Filipattos G, et al
    Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled.
    Eur Heart J. 2022 Jun 10. pii: 6605266. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. BRAUNWALD E
    Cardiac xenotransplantation: a new path for the treatment of advanced heart failure?
    Eur Heart J. 2022 Jun 4. pii: 6601572. doi: 10.1093.
    PubMed    
    
    
    
19. PABEL S, Sossalla S
    Atrial fibrillation and heart failure: novel insights into the chicken and egg dilemma.
    Eur Heart J. 2022 Jun 2. pii: 6599046. doi: 10.1093.
    PubMed    
    
    
    May 2022
20. METRA M, Pagnesi M, Claggett BL, Diaz R, et al
    Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial.
    Eur Heart J. 2022 May 22. pii: 6590348. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. CREA F
    Challenges in heart failure: from actionability of genetic variants in cardiopmyopathies to new therapeutic targets.
    Eur Heart J. 2022;43:1887-1890.
    PubMed    
    
    
    
22. VAN VELDHUISEN SL, Gorter TM, van Woerden G, de Boer RA, et al
    Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
    Eur Heart J. 2022;43:1955-1969.
    PubMed     Abstract available
    
    
    
23. PARK N, Marquez J, Pham TK, Ko TH, et al
    Cereblon contributes to cardiac dysfunction by degrading Cav1.2alpha.
    Eur Heart J. 2022;43:1973-1989.
    PubMed     Abstract available
    
    
    
24. BECHER PM, Lund LH, Coats AJS, Savarese G, et al
    An update on global epidemiology in heart failure.
    Eur Heart J. 2022 May 17. pii: 6586676. doi: 10.1093.
    PubMed    
    
    
    
25. BARITUSSIO A, Muthurangu V
    Cardiovascular magnetic resonance for the assessment of left ventricular filling pressure in heart failure.
    Eur Heart J. 2022 May 16. pii: 6586208. doi: 10.1093.
    PubMed    
    
    
    
26. ZHU Y, Ackers-Johnson M, Foo R
    T cells: a 'hidden corner' to be explored for treating heart failure.
    Eur Heart J. 2022 May 13. pii: 6585106. doi: 10.1093.
    PubMed    
    
    
    
27. FRANTZ S, Hundertmark MJ, Schulz-Menger J, Bengel FM, et al
    Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies.
    Eur Heart J. 2022 May 4. pii: 6578707. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. LINDE C
    CRT-P or CRT-D in heart failure patients: the RESET-CRT project-a prelude to the randomized controlled RESET-CRT study.
    Eur Heart J. 2022 May 3. pii: 6577069. doi: 10.1093.
    PubMed    
    
    
    
29. COWIE MR, Cleland JGF
    The COVID-19 pandemic and heart failure: lessons from GUIDE-HF.
    Eur Heart J. 2022 May 2. pii: 6576548. doi: 10.1093.
    PubMed    
    
    
    
30. TRIBOUILLOY C, Bohbot Y, Kubala M, Ruschitzka F, et al
    Characteristics, management, and outcomes of patients with multiple native valvular heart disease: a substudy of the EURObservational Research Programme Valvular Heart Disease II Survey.
    Eur Heart J. 2022 May 2. pii: 6576528. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
31. ECKHARDT CM, Balte PP, Barr RG, Bertoni AG, et al
    Lung function impairment and risk of incident heart failure: the NHLBI Pooled Cohorts Study.
    Eur Heart J. 2022 Apr 25. pii: 6573769. doi: 10.1093.
    PubMed     Abstract available
    
    
    
32. SHEN L, Jhund PS, Docherty KF, Vaduganathan M, et al
    Accelerated and personalized therapy for heart failure with reduced ejection fraction.
    Eur Heart J. 2022 Apr 25. pii: 6573857. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. MARON BA, Humbert M
    HFp2EF: heart failure with pulmonary dysfunction and preserved ejection fraction?
    Eur Heart J. 2022 Apr 25. pii: 6573597. doi: 10.1093.
    PubMed    
    
    
    
34. AKTAA S, Batra G, Cleland JGF, Coats A, et al
    Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart).
    Eur Heart J. 2022 Apr 20. pii: 6571493. doi: 10.1093.
    PubMed     Abstract available
    
    
    
35. VERBRUGGE FH, Borlaug BA
    Heart failure with normal natriuretic peptide levels: more fat, and that is the main problem.
    Eur Heart J. 2022 Apr 20. pii: 6571179. doi: 10.1093.
    PubMed    
    
    
    
36. VAN DER MEER P, Rienstra M, van Veldhuisen DJ
    A deleterious interaction between omecamtiv mecarbil and atrial fibrillation in patients with heart failure: an influence of digoxin?
    Eur Heart J. 2022 Apr 20. pii: 6571185. doi: 10.1093.
    PubMed    
    
    
    
37. OLIVELLA A, Mendez AB, Ferreira-Gonzalez I
    Mixing the fat with water: are normal natriuretic peptide heart failure with preserved ejection fraction patients just more obese?
    Eur Heart J. 2022 Apr 20. pii: 6571173. doi: 10.1093.
    PubMed    
    
    
    
38. CRESPO-LEIRO MG, Costanzo MR, Gustafsson F, Khush KK, et al
    Heart transplantation: focus on donor recovery strategies, left ventricular assist devices, and novel therapies.
    Eur Heart J. 2022 Apr 20. pii: 6571226. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. HONG S, Kim KS, Han K, Park CY, et al
    Acromegaly and cardiovascular outcomes: a cohort study.
    Eur Heart J. 2022;43:1491-1499.
    PubMed     Abstract available
    
    
    
40. WACHTER R, Rommel KP
    Hospitalization for heart failure: a window of opportunity.
    Eur Heart J. 2022 Apr 13. pii: 6568144. doi: 10.1093.
    PubMed    
    
    
    
41. TROMP J, Ouwerkerk W, Teng TK, Cleland JGF, et al
    Global disparities in prescription of guideline-recommended drugs for heart failure with reduced ejection fraction.
    Eur Heart J. 2022 Apr 8. pii: 6564923. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. KHAN MS, Bakris GL, Packer M, Shahid I, et al
    Kidney function assessment and endpoint ascertainment in clinical trials.
    Eur Heart J. 2022;43:1379-1400.
    PubMed     Abstract available
    
    
    March 2022
43. DMITRIEVA NI, Liu D, Wu CO, Boehm M, et al
    Middle age serum sodium levels in the upper part of normal range and risk of heart failure.
    Eur Heart J. 2022 Mar 29. pii: 6553797. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. SOLOMON SD, Claggett BL, Miao ZM, Diaz R, et al
    Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial.
    Eur Heart J. 2022 Mar 23. pii: 6552734. doi: 10.1093.
    PubMed     Abstract available
    
    
    
45. OKA S, Endo H, Takagi K, Yamagata K, et al
    Mechanical coronary artery stenosis induced by active fixation left ventricular lead: a case of acute complication after cardiac resynchronization therapy device implantation.
    Eur Heart J. 2022;43:1271.
    PubMed    
    
    
    
46. SHAH SJ
    BNP: Biomarker Not Perfect in heart failure with preserved ejection fraction.
    Eur Heart J. 2022 Mar 18. pii: 6550399. doi: 10.1093.
    PubMed    
    
    
    
47. SEQUEIRA V, Maack C
    Cereblon, a novel target in heart failure: but is calcium really everything?
    Eur Heart J. 2022 Mar 16. pii: 6549181. doi: 10.1093.
    PubMed    
    
    
    
48. 
    Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries.
    Eur Heart J. 2022;43:1104-1120.
    PubMed     Abstract available
    
    
    
49. 
    Corrigendum to: Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology.
    Eur Heart J. 2022 Mar 11. pii: 6546740. doi: 10.1093.
    PubMed    
    
    
    
50. ZILE MR, Desai AS, Costanzo MR, Ducharme A, et al
    The GUIDE-HF trial of pulmonary artery pressure monitoring in heart failure: impact of the COVID-19 pandemic.
    Eur Heart J. 2022 Mar 10. pii: 6546019. doi: 10.1093.
    PubMed     Abstract available
    
    
    
51. PRINZEN FW, Auricchio A, Mullens W, Linde C, et al
    Electrical management of heart failure: from pathophysiology to treatment.
    Eur Heart J. 2022 Mar 10. pii: 6546052. doi: 10.1093.
    PubMed     Abstract available
    
    
    
52. VOLPE M, Liuzzo G
    Unloading left heart with a shunt device shows no benefits in heart failure with preserved ejection fraction but supports the importance of phenotyping patients in clinical trials.
    Eur Heart J. 2022 Mar 8. pii: 6544808. doi: 10.1093.
    PubMed    
    
    
    February 2022
53. LIUZZO G, Patrono C
    In vivo generated chimeric antigen receptor T cells reduce fibrosis and restore cardiac function in experimental heart failure.
    Eur Heart J. 2022 Feb 21. pii: 6533290. doi: 10.1093.
    PubMed    
    
    
    
54. RUDOLPH V
    Heart and kidney: towards an integrated approach to secondary mitral regurgitation.
    Eur Heart J. 2022 Feb 18. pii: 6530471. doi: 10.1093.
    PubMed    
    
    
    
55. 
    Corrigendum to: PCSK9 Inhibition in Patients with Heart Failure - Neutral or harmful intervention?
    Eur Heart J. 2022 Feb 15. pii: 6529357. doi: 10.1093.
    PubMed    
    
    
    
56. MUTAGAYWA RK, Chin A, Karaye K, Bonny A, et al
    Unmet needs in the management of arrhythmias among heart failure patients in Africa.
    Eur Heart J. 2022 Feb 15. pii: 6528559. doi: 10.1093.
    PubMed    
    
    
    
57. BRAUNWALD E
    Heart failure: a 70 year Odysseydagger.
    Eur Heart J. 2022 Feb 15. pii: 6528592. doi: 10.1093.
    PubMed    
    
    
    
58. 
    Corrigendum to: Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
    Eur Heart J. 2022 Feb 9. pii: 6525416. doi: 10.1093.
    PubMed    
    
    
    
59. VERBRUGGE FH, Omote K, Reddy YNV, Sorimachi H, et al
    Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.
    Eur Heart J. 2022 Feb 9. pii: 6525335. doi: 10.1093.
    PubMed     Abstract available
    
    
    
60. BEOHAR N, Ailawadi G, Kotinkaduwa LN, Redfors B, et al
    Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial.
    Eur Heart J. 2022 Feb 3. pii: 6521532. doi: 10.1093.
    PubMed     Abstract available
    
    
    
61. CREA F
    Treatment of heart failure across the spectrum of left ventricular ejection fraction and an update on cardiac amyloidosis and ischaemic cardiomyopathy.
    Eur Heart J. 2022;43:351-354.
    PubMed    
    
    
    January 2022
62. RUILOPE LM, Ruiz-Hurtado G, Miranda B, Ortiz A, et al
    Use of chronic kidney disease blind spot to prevent cardiorenal outcomes.
    Eur Heart J. 2022;43:257-260.
    PubMed    
    
    
    
63. NIESSNER A, Drexel H
    PCSK9 inhibition in patients with heart failure: neutral or harmful intervention?
    Eur Heart J. 2022 Jan 13. pii: 6507289. doi: 10.1093.
    PubMed    
    
    
    
64. BAUERSACHS J, de Boer RA, Lindenfeld J, Bozkurt B, et al
    The year in cardiovascular medicine 2021: heart failure and cardiomyopathies.
    Eur Heart J. 2022 Jan 3. pii: 6491391. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
65. CREA F
    Sodium-glucose co-transporter inhibitors, iron therapy, and checkpoint inhibitors: new clinical and translational pieces of the heart failure puzzle.
    Eur Heart J. 2021;42:4871-4875.
    PubMed    
    
    
    
66. JOSEPH S, Panniyammakal J, Abdullakutty J, S S, et al
    The Cardiology Society of India-Kerala Acute Heart Failure Registry: poor adherence to guideline-directed medical therapy.
    Eur Heart J. 2021 Dec 21. pii: 6471440. doi: 10.1093.
    PubMed     Abstract available
    
    
    
67. ZANNAD F
    Management of heart failure around the globe. Are we doing enough?
    Eur Heart J. 2021 Dec 21. pii: 6471439. doi: 10.1093.
    PubMed    
    
    
    
68. MARTENS P, Dupont M, Dauw J, Nijst P, et al
    The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy-the IRON-CRT trial.
    Eur Heart J. 2021;42:4905-4914.
    PubMed     Abstract available
    
    
    
69. WHITE HD, Schwartz GG, Szarek M, Bhatt DL, et al
    Alirocumab after acute coronary syndrome in patients with a history of heart failure.
    Eur Heart J. 2021 Dec 18. pii: 6469637. doi: 10.1093.
    PubMed     Abstract available
    
    
    
70. ADAMO M, Gardner RS, McDonagh TA, Metra M, et al
    The 'Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
    Eur Heart J. 2021 Dec 18. pii: 6469680. doi: 10.1093.
    PubMed    
    
    
    
71. JANKOWSKA EA, Ponikowski P
    Dilemmas on diagnosis and treatment of iron deficiency in patients after an episode of acute heart failure.
    Eur Heart J. 2021 Dec 9. pii: 6458058. doi: 10.1093.
    PubMed    
    
    
    
72. SAWICKI KT, Ardehali H
    Iron therapy on quality of life in acute heart failure: alternative approaches.
    Eur Heart J. 2021 Dec 9. pii: 6458062. doi: 10.1093.
    PubMed    
    
    
    
73. KONDO T, McMurray JJV
    Re-emergence of heart failure with a normal ejection fraction?
    Eur Heart J. 2021 Dec 8. pii: 6455984. doi: 10.1093.
    PubMed    
    
    
    
74. BUTLER J, Packer M, Filippatos G, Ferreira JP, et al
    Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction.
    Eur Heart J. 2021 Dec 8. pii: 6455932. doi: 10.1093.
    PubMed     Abstract available
    
    
    
75. COATS AJS, Heymans S, Farmakis D, Anker SD, et al
    Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology.
    Eur Heart J. 2021 Dec 7. pii: 6454842. doi: 10.1093.
    PubMed    
    
    
    
76. VOLPE M, Patrono C
    The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction.
    Eur Heart J. 2021;42:4621-4623.
    PubMed    
    
    
    November 2021
77. ROALFE AK, Lay-Flurrie SL, Ordonez-Mena JM, Goyder CR, et al
    Long term trends in natriuretic peptide testing for heart failure in UK primary care: a cohort study.
    Eur Heart J. 2021 Nov 30. pii: 6437771. doi: 10.1093.
    PubMed     Abstract available
    
    
    
78. CRUMP C, Sundquist J, McLaughlin MA, Dolan SM, et al
    Pre-term delivery and long-term risk of heart failure in women: a national cohort and co-sibling study.
    Eur Heart J. 2021 Nov 24. pii: 6438093. doi: 10.1093.
    PubMed     Abstract available
    
    
    
79. CREA F
    Mechanisms of heart failure with preserved ejection fraction, risk stratification of heart failure with reduced ejection fraction, and new light on resistance to diuretics in acute decompensated heart failure.
    Eur Heart J. 2021;42:4405-4409.
    PubMed    
    
    
    
80. PITT B, Ferreira JP, Zannad F
    Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI.
    Eur Heart J. 2021 Nov 12. pii: 6425576. doi: 10.1093.
    PubMed    
    
    
    
81. ISHIURA J, Nakamori S, Ishida M, Dohi K, et al
    'Targeting the cardiac myocyte and fibrosis' in heart failure.
    Eur Heart J. 2021 Nov 10. pii: 6425003. doi: 10.1093.
    PubMed    
    
    
    
82. LUND LH, Hage C, Savarese G
    Implementation science and potential for screening in heart failure.
    Eur Heart J. 2021 Nov 9. pii: 6424186. doi: 10.1093.
    PubMed    
    
    
    
83. EGIDY ASSENZA G, Dimopoulos K, Budts W, Donti A, et al
    Management of acute cardiovascular complications in pregnancy.
    Eur Heart J. 2021;42:4224-4240.
    PubMed     Abstract available
    
    
    October 2021
84. BUTLER J, Anker SD, Filippatos G, Usman MS, et al
    Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations.
    Eur Heart J. 2021 Oct 30. pii: 6414464. doi: 10.1093.
    PubMed    
    
    
    
85. SEFEROVIC PM, Piepoli M, Polovina M, Milinkovic I, et al
    ESC/HFA Quality of Care Centres: the ultimate frontier in unifying heart failure management.
    Eur Heart J. 2021 Oct 28. pii: 6413707. doi: 10.1093.
    PubMed    
    
    
    
86. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
    Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the
    Eur Heart J. 2021 Oct 14. pii: 6397185. doi: 10.1093.
    PubMed    
    
    
    
87. BRAUNWALD E
    Heart failure with preserved ejection fraction: a stepchild no more!
    Eur Heart J. 2021;42:3900-3901.
    PubMed    
    
    
    
88. SATTAR N, Anker SD, Butler J, Verma S, et al
    Obesity, heart failure, and SGLT2 inhibition: DECLARE-TIMI 58 provides insights.
    Eur Heart J. 2021 Oct 7. pii: 6383062. doi: 10.1093.
    PubMed    
    
    
    
89. LINDE C
    Pace and ablate better than drugs in patients with heart failure and atrial fibrillation: lessons from the APAF-CRT mortality trial.
    Eur Heart J. 2021 Oct 6. pii: 6382271. doi: 10.1093.
    PubMed    
    
    
    September 2021
90. CREA F
    The ESC Guidelines on heart failure, sacubitril-valsartan in resistant hypertension, and new therapeutic targets in myocardial hypertrophy.
    Eur Heart J. 2021;42:3581-3585.
    PubMed    
    
    
    
91. ZHAO Y, Ling S, Li J, Zhong G, et al
    3' untranslated region of Ckip-1 inhibits cardiac hypertrophy independently of its cognate protein.
    Eur Heart J. 2021;42:3786-3799.
    PubMed     Abstract available
    
    
    
92. CHEN QQ, Ma G, Liu JF, Cai YY, et al
    Neuraminidase 1 is a driver of experimental cardiac hypertrophy.
    Eur Heart J. 2021;42:3770-3782.
    PubMed     Abstract available
    
    
    
93. WUSSLER D, Mueller C
    Biomarker-driven prognostic model for risk prediction in heart failure: ready for Prime time?
    Eur Heart J. 2021 Sep 17. pii: 6371853. doi: 10.1093.
    PubMed    
    
    
    
94. SINHA A, Rahman H, Webb A, Shah AM, et al
    Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.
    Eur Heart J. 2021 Sep 16. pii: 6371296. doi: 10.1093.
    PubMed     Abstract available
    
    
    
95. MARTENS P, Tang WHW, Mullens W
    Renal sodium avidity, the prevailing renal target in heart failure.
    Eur Heart J. 2021 Sep 16. pii: 6371295. doi: 10.1093.
    PubMed    
    
    
    
96. COX ZL, Rao VS, Ivey-Miranda JB, Moreno-Villagomez J, et al
    Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure.
    Eur Heart J. 2021 Sep 16. pii: 6371304. doi: 10.1093.
    PubMed     Abstract available
    
    
    
97. 
    Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
    Eur Heart J. 2021 Sep 14. pii: 6370281. doi: 10.1093.
    PubMed    
    
    
    
98. JANKOWSKA EA, Ponikowski P
    Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?
    Eur Heart J. 2021 Sep 14. pii: 6370026. doi: 10.1093.
    PubMed    
    
    
    
99. CREA F
    The ESC Guidelines on cardiac pacing and resynchronization, and the many facets of atrial fibrillation.
    Eur Heart J. 2021;42:3411-3414.
    PubMed    
    
    
    
100. GLIKSON M, Nielsen JC, Kronborg MB, Michowitz Y, et al
     2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.
     Eur Heart J. 2021;42:3427-3520.
     PubMed    
     
     
     
101. BAYES-GENIS A, Diez J
     Transition to heart failure in hypertension: going to the heart of the matter.
     Eur Heart J. 2021 Sep 13. pii: 6369562. doi: 10.1093.
     PubMed    
     
     
     
102. LEWIS EF
     A fourth pillar for all in the treatment of heart failure.
     Eur Heart J. 2021 Sep 13. pii: 6369563. doi: 10.1093.
     PubMed    
     
     
     
103. KAHN M, Grayson AD, Chaggar PS, Ng Kam Chuen MJ, et al
     Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.
     Eur Heart J. 2021 Sep 11. pii: 6368904. doi: 10.1093.
     PubMed     Abstract available
     
     
     
104. BROWN JM, Zhou W, Weber B, Divakaran S, et al
     Low coronary flow relative to myocardial mass predicts heart failure in symptomatic hypertensive patients with no obstructive coronary artery disease.
     Eur Heart J. 2021 Sep 7. pii: 6365821. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2021
105. YILMAZ MB
     Does early angiography pave the way for improved outcomes in patients with acute heart failure?
     Eur Heart J. 2021 Aug 31. pii: 6360027. doi: 10.1093.
     PubMed    
     
     
     
106. MCDONAGH TA, Metra M, Adamo M, Gardner RS, et al
     2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
     Eur Heart J. 2021 Aug 27. pii: 6358045. doi: 10.1093.
     PubMed    
     
     
     
107. LIGHT PE
     Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure.
     Eur Heart J. 2021 Aug 27. pii: 6358226. doi: 10.1093.
     PubMed    
     
     
     
108. CURTAIN JP, Docherty KF, Jhund PS, Petrie MC, et al
     Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.
     Eur Heart J. 2021 Aug 27. pii: 6358075. doi: 10.1093.
     PubMed     Abstract available
     
     
     
109. POCOCK SJ, Ferreira JP, Gregson J, Anker SD, et al
     Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Aug 23. pii: 6356321. doi: 10.1093.
     PubMed     Abstract available
     
     
     
110. CREA F
     The complex relationship among heart failure, cancer, and lipid lowering, and an update on cardiomyopathies.
     Eur Heart J. 2021;42:3029-3032.
     PubMed    
     
     
     
111. BERGER M, Solelhac G, Roche F, Heinzer R, et al
     Insomnia, a new modifiable risk factor for heart failure?
     Eur Heart J. 2021 Aug 21. pii: 6355986. doi: 10.1093.
     PubMed    
     
     
     
112. WITHAAR C, Lam CSP, Schiattarella GG, de Boer RA, et al
     Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models.
     Eur Heart J. 2021 Aug 20. pii: 6355308. doi: 10.1093.
     PubMed     Abstract available
     
     
     
113. KEMPF T
     Iron supplementation in acute heart failure: energize your life.
     Eur Heart J. 2021;42:3021-3022.
     PubMed    
     
     
     
114. VOLPE M, Gallo G
     Sacubitril/valsartan for heart failure with preserved ejection fraction and resistant hypertension: one shot for a double strike?
     Eur Heart J. 2021 Aug 15. pii: 6352588. doi: 10.1093.
     PubMed    
     
     
     
115. MAHMOOD A, Ray M, Dobalian A, Ward KD, et al
     Insomnia symptoms and incident heart failure: a population-based cohort study.
     Eur Heart J. 2021 Aug 15. pii: 6352589. doi: 10.1093.
     PubMed     Abstract available
     
     
     
116. WAGNER JUG, Dimmeler S
     The endothelial niche in heart failure: from development to regeneration.
     Eur Heart J. 2021 Aug 15. pii: 6352586. doi: 10.1093.
     PubMed    
     
     
     
117. JACKSON AM, Jhund PS, Anand IS, Dungen HD, et al
     Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
     Eur Heart J. 2021 Aug 15. pii: 6352587. doi: 10.1093.
     PubMed     Abstract available
     
     
     
118. DIVAKARAN S, Nohria A
     Decoding the link between heart failure and incident cancer.
     Eur Heart J. 2021 Aug 14. pii: 6352225. doi: 10.1093.
     PubMed    
     
     
     
119. WANG N, Sun Y, Zhang H, Wang B, et al
     Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.
     Eur Heart J. 2021 Aug 10. pii: 6347324. doi: 10.1093.
     PubMed     Abstract available
     
     
     
120. NICHOLLS M
     New perspectives on heart failure.
     Eur Heart J. 2021 Aug 6. pii: 6343116. doi: 10.1093.
     PubMed    
     
     
     July 2021
121. KOSYAKOVSKY LB, Austin PC, Ross HJ, Wang X, et al
     Early invasive coronary angiography and acute ischaemic heart failure outcomes.
     Eur Heart J. 2021 Jul 30. pii: 6331345. doi: 10.1093.
     PubMed     Abstract available
     
     
     
122. TUAL-CHALOT S, Stellos K
     Drug repurposing to prevent pressure overload-induced cardiac hypertrophy and heart failure.
     Eur Heart J. 2021 Jul 13. pii: 6319852. doi: 10.1093.
     PubMed    
     
     
     
123. DA DALT L, Castiglioni L, Baragetti A, Audano M, et al
     PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.
     Eur Heart J. 2021 Jul 12. pii: 6319627. doi: 10.1093.
     PubMed     Abstract available
     
     
     
124. 
     European Heart Journal Team Heart Failure.
     Eur Heart J. 2021 Jul 5. pii: 6314555. doi: 10.1093.
     PubMed    
     
     
     
125. ONO M, Garg S, Onuma Y, Serruys PW, et al
     Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?
     Eur Heart J. 2021 Jul 1. pii: 6311994. doi: 10.1093.
     PubMed    
     
     
     June 2021
126. LAM CSP, Ferreira JP, Pfarr E, Sim D, et al
     Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Jun 29. pii: 6310468. doi: 10.1093.
     PubMed     Abstract available
     
     
     
127. REN QW, Yu SY, Teng TK, Li X, et al
     Statin associated lower cancer risk and related mortality in patients with heart failure.
     Eur Heart J. 2021 Jun 22. pii: 6307232. doi: 10.1093.
     PubMed     Abstract available
     
     
     
128. CREA F
     The Universal Definition of Heart Failure, risk prediction in cardiogenic shock, artificial intelligence in cardiac allograft rejection, and the genetics of dilated cardiomyopathy.
     Eur Heart J. 2021;42:2317-2320.
     PubMed    
     
     
     
129. NICHOLLS M
     Recognition for heart failure breakthrough.
     Eur Heart J. 2021 Jun 11. pii: 6296965. doi: 10.1093.
     PubMed    
     
     
     
130. JANKOWSKA EA, Kirwan BA, Kosiborod M, Butler J, et al
     The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.
     Eur Heart J. 2021 Jun 3. pii: 6291468. doi: 10.1093.
     PubMed     Abstract available
     
     
     
131. ZANNAD F, Cotter G, Alonso Garcia A, George S, et al
     What can heart failure trialists learn from oncology trialists?
     Eur Heart J. 2021 Jun 2. pii: 6291019. doi: 10.1093.
     PubMed     Abstract available
     
     
     May 2021
132. VOLZ S, Redfors B, Angeras O, Ioanes D, et al
     Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
     Eur Heart J. 2021 May 23. pii: 6282431. doi: 10.1093.
     PubMed     Abstract available
     
     
     
133. MARSTON NA, Han L, Olivotto I, Day SM, et al
     Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy.
     Eur Heart J. 2021;42:1988-1996.
     PubMed     Abstract available
     
     
     
134. PORCHER R, Desguerre I, Amthor H, Chabrol B, et al
     Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
     Eur Heart J. 2021;42:1976-1984.
     PubMed     Abstract available
     
     
     
135. NICHOLLS M
     Telemedicine for chronic heart failure patients.
     Eur Heart J. 2021 May 13. pii: 6274945. doi: 10.1093.
     PubMed    
     
     
     
136. HAMDANI N, Costantino S, Mugge A, Lebeche D, et al
     Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies.
     Eur Heart J. 2021 May 5. pii: 6264879. doi: 10.1093.
     PubMed     Abstract available
     
     
     April 2021
137. 
     Corrigendum to: Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
     Eur Heart J. 2021 Apr 24. pii: 6248970. doi: 10.1093.
     PubMed    
     
     
     
138. CREA F
     Emerging causes and risk factors of heart failure: amyloidosis, myocarditis, immune checkpoint inhibitors, air pollution, and visceral adipose tissue.
     Eur Heart J. 2021;42:1533-1537.
     PubMed    
     
     
     
139. RAJAGOPALAN S, Brook RD, Al-Kindi S
     Air pollution and flooding in the lungs: modern insights into ancient problems.
     Eur Heart J. 2021;42:1592-1594.
     PubMed    
     
     
     
140. WITHAAR C, Meems LMG, de Boer RA
     Fighting HFpEF in women: taking aim at belly fat.
     Eur Heart J. 2021;42:1606-1608.
     PubMed    
     
     
     
141. FULLENKAMP DE, Puckelwartz MJ, McNally EM
     Genome-wide association for heart failure: from discovery to clinical use.
     Eur Heart J. 2021 Apr 14. pii: 6225796. doi: 10.1093.
     PubMed    
     
     
     
142. 
     Erratum to: Conducting Clinical Trials in Heart Failure During (and After) the COVID-19 Pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2021 Apr 7. pii: 6214477. doi: 10.1093.
     PubMed    
     
     
     
143. BAUERSACHS J
     The struggle towards a Universal Definition of Heart Failure-how to proceed?
     Eur Heart J. 2021 Apr 1. pii: 6206998. doi: 10.1093.
     PubMed    
     
     
     March 2021
144. CREA F
     Challenges in heart failure: quality of life, chronic kidney disease, and secondary mitral regurgitation.
     Eur Heart J. 2021;42:1185-1189.
     PubMed    
     
     
     
145. SPERTUS JA
     Quality of life in EMPEROR-Reduced: emphasizing what is important to patients while identifying strategies to support more patient-centred care.
     Eur Heart J. 2021;42:1213-1215.
     PubMed    
     
     
     
146. FUKUOKA R, Kawamura A, Kohsaka S
     Prediction of sudden arrhythmic death in patients with heart failure: towards validation in a worldwide broader range of patients.
     Eur Heart J. 2021 Mar 18. pii: 6177055. doi: 10.1093.
     PubMed    
     
     
     
147. COATS AJS, Anker SD, Baumbach A, Alfieri O, et al
     The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and
     Eur Heart J. 2021 Mar 18. pii: 6174642. doi: 10.1093.
     PubMed     Abstract available
     
     
     
148. YOUNIS A, Goldenberg I
     Extending the MADIT-ICD benefit score to heterogenous heart failure populations.
     Eur Heart J. 2021 Mar 18. pii: 6177051. doi: 10.1093.
     PubMed    
     
     
     
149. VOLPE M, Patrono C
     The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending.
     Eur Heart J. 2021 Mar 10. pii: 6168016. doi: 10.1093.
     PubMed    
     
     
     
150. GARNIER S, Harakalova M, Weiss S, Mokry M, et al
     Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23.
     Eur Heart J. 2021 Mar 3. pii: 6157424. doi: 10.1093.
     PubMed     Abstract available
     
     
     
151. VAN DIEPEN S, Armstrong PW
     Learning whether to subtract beta-blockers: it's about time.
     Eur Heart J. 2021;42:915-918.
     PubMed     Abstract available
     
     
     February 2021
152. VOLPE M, Patrono C
     Iron heart.
     Eur Heart J. 2021;42:809-810.
     PubMed    
     
     
     
153. DIDERIKSEN JR, Christiansen MK, Johansen JB, Nielsen JC, et al
     Long-term outcomes in young patients with atrioventricular block of unknown aetiology.
     Eur Heart J. 2021 Feb 18. pii: 6143533. doi: 10.1093.
     PubMed     Abstract available
     
     
     
154. VILLRINGER A, Laufs U
     Heart failure, cognition, and brain damage.
     Eur Heart J. 2021 Feb 16. pii: 6139887. doi: 10.1093.
     PubMed    
     
     
     
155. HALLIDAY BP, Senior R, Pennell DJ
     Assessing left ventricular systolic function: from ejection fraction to strain analysis.
     Eur Heart J. 2021;42:789-797.
     PubMed     Abstract available
     
     
     
156. CREA F
     New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease.
     Eur Heart J. 2021;42:551-554.
     PubMed    
     
     
     
157. 
     Corrigendum to: The Year in Cardiovascular Medicine: Heart Failure and Cardiomyopathies. The Year in Cardiovascular Medicine 2020.
     Eur Heart J. 2021 Feb 11. pii: 6132731. doi: 10.1093.
     PubMed    
     
     
     
158. PETRIE MC, Lee MM, Lang NN
     EMPEROR-REDUCED reigns while EMPERIAL whimpers.
     Eur Heart J. 2021;42:711-714.
     PubMed    
     
     
     
159. WANG M, Zhou T, Song Y, Li X, et al
     Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank.
     Eur Heart J. 2021 Feb 2. pii: 6126215. doi: 10.1093/eurheartj/ehaa1031.
     PubMed     Abstract available
     
     
     January 2021
160. LOCH A, Koh PS, Manokaran P
     Giant hepatic cyst masquerading as right heart failure.
     Eur Heart J. 2021 Jan 30. pii: 6124029. doi: 10.1093.
     PubMed    
     
     
     
161. FREY A, Homola GA, Henneges C, Muhlbauer L, et al
     Temporal changes in total and hippocampal brain volume and cognitive function in patients with chronic heart failure-the COGNITION.MATTERS-HF cohort study.
     Eur Heart J. 2021 Jan 26. pii: 6120261. doi: 10.1093.
     PubMed     Abstract available
     
     
     
162. 
     Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?
     Eur Heart J. 2021;42:319.
     PubMed    
     
     
     
163. MASSIMO V, Carlo P
     Truly galactic?
     Eur Heart J. 2021;42:296-297.
     PubMed    
     
     
     
164. EVANS MA, Sano S, Walsh K
     Clonal haematopoiesis and cardiovascular disease: how low can you go?
     Eur Heart J. 2021;42:266-268.
     PubMed    
     
     
     
165. SMISETH OA, Aalen JM, Skulstad H
     Heart failure and systolic function: time to leave diagnostics based on ejection fraction?
     Eur Heart J. 2021 Jan 17. pii: 6075085. doi: 10.1093.
     PubMed    
     
     
     
166. BAUERSACHS J
     Heart failure drug treatment: the fantastic four.
     Eur Heart J. 2021 Jan 14. pii: 6099035. doi: 10.1093/eurheartj/ehaa1012.
     PubMed    
     
     
     
167. CSENGERI D, Sprunker NA, Di Castelnuovo A, Niiranen T, et al
     Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes.
     Eur Heart J. 2021 Jan 13. pii: 6090248. doi: 10.1093.
     PubMed     Abstract available
     
     
     
168. HOLT A, Blanche P, Zareini B, Rajan D, et al
     Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.
     Eur Heart J. 2021 Jan 11. pii: 6082772. doi: 10.1093/eurheartj/ehaa1058.
     PubMed     Abstract available
     
     
     
169. PACKER M, Anker SD, Butler J, Filippatos G, et al
     Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Jan 11. pii: 6081935. doi: 10.1093.
     PubMed     Abstract available
     
     
     
170. BUTLER J, Anker SD, Filippatos G, Khan MS, et al
     Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.
     Eur Heart J. 2021 Jan 9. pii: 6072066. doi: 10.1093/eurheartj/ehaa1007.
     PubMed     Abstract available
     
     
     
171. CREA F
     Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun.
     Eur Heart J. 2021;42:139-142.
     PubMed    
     
     
     
172. DEVAUX Y, Badimon L
     CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease.
     Eur Heart J. 2021;42:202-204.
     PubMed    
     
     
     
173. AGARWAL R, Kolkhof P, Bakris G, Bauersachs J, et al
     Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
     Eur Heart J. 2021;42:152-161.
     PubMed     Abstract available
     
     
     
174. FURHOLZ M, Gisler F, Hunziker L, Huber AT, et al
     Posture dependent dynamic external outflow graft compression in HeartMate 3TM left ventricular assist device.
     Eur Heart J. 2021;42:205.
     PubMed    
     
     
     
175. BUENO H, Moura B, Lancellotti P, Bauersachs J, et al
     The year in cardiovascular medicine 2020: heart failure and cardiomyopathies.
     Eur Heart J. 2021 Jan 3. pii: 6060054. doi: 10.1093/eurheartj/ehaa1061.
     PubMed    
     
     
     December 2020
176. 
     Corrigendum to: How to Diagnose Heart Failure with Preserved Ejection Fraction - The HFA-PEFF-SCORE An updated Consensus Statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2020 Dec 29. pii: 6055039. doi: 10.1093/eurheartj/ehaa1016.
     PubMed    
     
     
     
177. ABRAHAM WT, Lindenfeld J, Ponikowski P, Agostoni P, et al
     Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
     Eur Heart J. 2020 Dec 22. pii: 6044442. doi: 10.1093.
     PubMed     Abstract available
     
     
     
178. BAKER AH, Giacca M
     Antagonism of miRNA in heart failure: first evidence in human.
     Eur Heart J. 2020 Dec 18. pii: 6041762. doi: 10.1093.
     PubMed    
     
     
     
179. ROY R, Koch WJ
     Adding another GRK to the fire of heart failure.
     Eur Heart J. 2020 Dec 7. pii: 6025474. doi: 10.1093.
     PubMed    
     
     
     November 2020
180. PITT B, Byrd JB
     Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
     Eur Heart J. 2020 Nov 30. pii: 6012925. doi: 10.1093.
     PubMed    
     
     
     
181. ASSMUS B, Cremer S, Kirschbaum K, Culmann D, et al
     Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
     Eur Heart J. 2020 Nov 26. pii: 6006386. doi: 10.1093.
     PubMed     Abstract available
     
     
     
182. SORIMACHI H, Obokata M, Takahashi N, Reddy YNV, et al
     Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction.
     Eur Heart J. 2020 Nov 23. pii: 5998959. doi: 10.1093.
     PubMed     Abstract available
     
     
     
183. BOHM M, Mahfoud F
     J-curve revisited.
     Eur Heart J. 2020;41:4283.
     PubMed    
     
     
     
184. LIEW CH, McEvoy JW
     The diastolic blood pressure J-curve remains an observational research phenomenon that has not yet been proven as causal and should not be used to make invasive treatment decisions.
     Eur Heart J. 2020;41:4284-4285.
     PubMed    
     
     
     
185. FEDCHENKO M, Mandalenakis Z, Giang KW, Rosengren A, et al
     Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study.
     Eur Heart J. 2020 Nov 21. pii: 5997447. doi: 10.1093.
     PubMed     Abstract available
     
     
     
186. CLELAND JGF, Ferreira JP, Mariottoni B, Pellicori P, et al
     The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
     Eur Heart J. 2020 Nov 20. pii: 5993916. doi: 10.1093.
     PubMed     Abstract available
     
     
     
187. ALFONSO F
     Heart Failure 2019.
     Eur Heart J. 2020 Nov 17. pii: 5986679. doi: 10.1093.
     PubMed    
     
     
     
188. TAUBEL J, Hauke W, Rump S, Viereck J, et al
     Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study.
     Eur Heart J. 2020 Nov 11. pii: 5974817. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2020
189. 
     Corrigendum to: Treatment of heart failure with reduced ejection fraction: the dawn of sodium-glucose cotransporter-2 inhibitors.
     Eur Heart J. 2020 Oct 22. pii: 5935857. doi: 10.1093.
     PubMed    
     
     
     
190. BATKAI S, Genschel C, Viereck J, Rump S, et al
     CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
     Eur Heart J. 2020 Oct 22. pii: 5934677. doi: 10.1093.
     PubMed     Abstract available
     
     
     
191. CREA F
     The multiple causes and treatments of heart failure: focus on genetic and molecular mechanisms and non-pharmacological interventions.
     Eur Heart J. 2020;41:3769-3773.
     PubMed    
     
     
     
192. BONNET M, Champagnac A, Lantelme P, Harbaoui B, et al
     Endomyocardial biopsy findings in Kawasaki-like disease associated with SARS-CoV-2.
     Eur Heart J. 2020;41:3863-3864.
     PubMed    
     
     
     
193. PETTIT SJ
     HeartMate 3: real-world performance matches pivotal trial.
     Eur Heart J. 2020;41:3810-3812.
     PubMed    
     
     
     
194. LIUZZO G, Patrono C
     EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial.
     Eur Heart J. 2020 Oct 7. pii: 5918827. doi: 10.1093.
     PubMed    
     
     
     September 2020
195. CREA F
     Treatment of heart failure: the dawn of the era of sodium-glucose co-transporter-2 inhibitors.
     Eur Heart J. 2020;41:3379-3383.
     PubMed    
     
     
     
196. 
     Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure? [Eur Heart J 2020;41: 2411].
     Eur Heart J. 2020 Sep 15. pii: 5906090. doi: 10.1093.
     PubMed    
     
     
     
197. BUTLER J, Zannad F, Filippatos G, Anker SD, et al
     Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice.
     Eur Heart J. 2020 Sep 15. pii: 5906091. doi: 10.1093.
     PubMed    
     
     
     
198. SAVARESE G, Cosentino F
     The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns.
     Eur Heart J. 2020 Sep 9. pii: 5903162. doi: 10.1093.
     PubMed    
     
     
     August 2020
199. SERENELLI M, Bohm M, Inzucchi SE, Kober L, et al
     Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).
     Eur Heart J. 2020 Aug 21. pii: 5895186. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2020
200. HARARI R, Bangalore S
     Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!
     Eur Heart J. 2020 Jul 30. pii: 5879119. doi: 10.1093.
     PubMed    
     
     
     
201. FIGLIOZZI S, Rizzo S, De Gaspari M, Tarantini G, et al
     End-stage heart failure secondary to low-dose hydroxychloroquine treatment.
     Eur Heart J. 2020 Jul 29. pii: 5877566. doi: 10.1093.
     PubMed    
     
     
     
202. 
     Corrigendum to: How to slice the pie: heart failure subgroups and their clinical meaning.
     Eur Heart J. 2020 Jul 25. pii: 5876171. doi: 10.1093.
     PubMed    
     
     
     
203. ESCANED J, Lerman LO
     Coronary microcirculation and hypertensive heart failure.
     Eur Heart J. 2020;41:2376-2378.
     PubMed    
     
     
     
204. LUSCHER TF
     How to slice the pie: heart failure subgroups and their clinical meaning.
     Eur Heart J. 2020;41:2339-2343.
     PubMed    
     
     
     
205. SCHMIDT IM, Verma A, Waikar SS
     Circulating plasma angiotensin-converting enzyme 2 concentrations in patients with kidney disease.
     Eur Heart J. 2020;41:3097-3098.
     PubMed    
     
     
     June 2020
206. KARASON K, Jamaly S
     Heart failure development in obesity: mechanistic pathways.
     Eur Heart J. 2020 Jun 18. pii: 5859181. doi: 10.1093.
     PubMed    
     
     
     
207. ZHOU Y, Liu F, Nie J
     Does hypoperfusion outperformed blood pressure as a better predictor in the risk stratification of acute heart failure?
     Eur Heart J. 2020 Jun 18. pii: 5859700. doi: 10.1093.
     PubMed    
     
     
     
208. BOCCHINO PP, Angelini F, Frea S
     Intravenous vasodilators in acute heart failure patients with low basic blood pressure: may the benefit come from targeting perfusion rather than pressure?
     Eur Heart J. 2020 Jun 18. pii: 5859697. doi: 10.1093.
     PubMed    
     
     
     
209. KIM J, Kang D, Park H, Kang M, et al
     Long-term beta-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.
     Eur Heart J. 2020 Jun 15. pii: 5857797. doi: 10.1093.
     PubMed     Abstract available
     
     
     
210. ANKER SD, Butler J, Khan MS, Abraham WT, et al
     Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).
     Eur Heart J. 2020 Jun 4. pii: 5851435. doi: 10.1093.
     PubMed     Abstract available
     
     
     
211. CULEBRAS E, Hernandez F
     ACE2 is on the X chromosome: could this explain COVID-19 gender differences?
     Eur Heart J. 2020;41:3095.
     PubMed    
     
     
     May 2020
212. PACKER M
     Longevity genes, cardiac ageing, and the pathogenesis of cardiomyopathy: implications for understanding the effects of current and future treatments for heart failure.
     Eur Heart J. 2020 May 27. pii: 5847945. doi: 10.1093.
     PubMed     Abstract available
     
     
     
213. SAMA IE, Ravera A, Santema BT, van Goor H, et al
     Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors.
     Eur Heart J. 2020;41:1810-1817.
     PubMed     Abstract available
     
     
     
214. OUDIT GY, Pfeffer MA
     Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19.
     Eur Heart J. 2020;41:1818-1820.
     PubMed    
     
     
     
215. INCIARDI RM, Adamo M, Lupi L, Cani DS, et al
     Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy.
     Eur Heart J. 2020;41:1821-1829.
     PubMed     Abstract available
     
     
     
216. THUM T
     SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?
     Eur Heart J. 2020 May 8. pii: 5834515. doi: 10.1093.
     PubMed    
     
     
     
217. OZKAN J
     Trying times for heart failure trials during the COVID-19 pandemic.
     Eur Heart J. 2020;41:1715.
     PubMed    
     
     
     
218. LUSCHER TF
     Cardio-oncology and the future of heart failure.
     Eur Heart J. 2020;41:1709-1712.
     PubMed    
     
     
     
219. PITT B
     Mark Nicholls speaks to Professor Bertram Pitt and his role as a pioneer in cardiology over the management of heart failure.
     Eur Heart J. 2020;41:1615-1617.
     PubMed    
     
     
     
220. MILLER VM
     Universality of sex differences in cardiovascular outcomes: where do we go from here?
     Eur Heart J. 2020;41:1697-1699.
     PubMed    
     
     
     April 2020
221. PACKER M
     Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of care.
     Eur Heart J. 2020 Apr 29. pii: 5827051. doi: 10.1093.
     PubMed    
     
     
     
222. BOHM M, Bewarder Y, Kindermann I
     Ejection fraction in heart failure revisited- where does the evidence start?
     Eur Heart J. 2020 Apr 29. pii: 5827050. doi: 10.1093.
     PubMed    
     
     
     
223. BARTKO PE, Hulsmann M, Hung J, Pavo N, et al
     Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction.
     Eur Heart J. 2020 Apr 29. pii: 5827049. doi: 10.1093.
     PubMed     Abstract available
     
     
     
224. BAYES-GENIS A, Liu PP, Lanfear DE, de Boer RA, et al
     Omics phenotyping in heart failure: the next frontier.
     Eur Heart J. 2020 Apr 26. pii: 5825477. doi: 10.1093.
     PubMed     Abstract available
     
     
     
225. TAHARA A, Tahara N, Maeda-Ogata S, Bekki M, et al
     Brown adipose tissue activation in severe heart failure.
     Eur Heart J. 2020 Apr 24. pii: 5824912. doi: 10.1093.
     PubMed    
     
     
     
226. LUSCHER TF
     Sex and gender and cardiovascular medicine: impact in diabetes, acute coronary syndromes, and heart failure.
     Eur Heart J. 2020;41:1311-1314.
     PubMed    
     
     
     March 2020
227. LAM CSP, Voors AA, Piotr P, McMurray JJV, et al
     Time to rename the middle child of heart failure: heart failure with mildly reduced ejection fraction.
     Eur Heart J. 2020 Mar 30. pii: 5813810. doi: 10.1093.
     PubMed    
     
     
     
228. VADUGANATHAN M, Jhund PS, Claggett BL, Packer M, et al
     A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
     Eur Heart J. 2020 Mar 28. pii: 5813082. doi: 10.1093.
     PubMed     Abstract available
     
     
     
229. ZHOU W, Brown JM, Bajaj NS, Chandra A, et al
     Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure.
     Eur Heart J. 2020 Mar 28. pii: 5813079. doi: 10.1093.
     PubMed     Abstract available
     
     
     
230. DOCHERTY KF, Jhund PS, Inzucchi SE, Kober L, et al
     Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.
     Eur Heart J. 2020 Mar 28. pii: 5813081. doi: 10.1093.
     PubMed     Abstract available
     
     
     
231. VAN DER LINGEN ACJ, Allaart CP
     The role of implantable cardioverter-defibrillators in New York Heart Class I heart failure patients: do not abandon the asymptomatic just yet.
     Eur Heart J. 2020 Mar 25. pii: 5811615. doi: 10.1093.
     PubMed    
     
     
     
232. GOLDENBERG I, Huang DT, Nielsen JC
     The role of implantable cardioverter-defibrillators in asymptomatic patients with left ventricular dysfunction.
     Eur Heart J. 2020 Mar 25. pii: 5811613. doi: 10.1093.
     PubMed    
     
     
     
233. LUSCHER TF
     Ejection fraction to classify heart failure: are we using the right thing?
     Eur Heart J. 2020;41:1219-1222.
     PubMed    
     
     
     
234. MOTIEJUNAITE J, Akiyama E, Cohen-Solal A, Maggioni AP, et al
     The association of long-term outcome and biological sex in patients with acute heart failure from different geographic regions.
     Eur Heart J. 2020 Mar 3. pii: 5775572. doi: 10.1093.
     PubMed     Abstract available
     
     
     
235. SLIWA K
     Heart failure can affect everyone: the ESC Geoffrey Rose lecture.
     Eur Heart J. 2020 Mar 2. pii: 5771280. doi: 10.1093.
     PubMed     Abstract available
     
     
     
236. BOHM M, Ferreira JP, Mahfoud F, Duarte K, et al
     Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial.
     Eur Heart J. 2020 Mar 2. pii: 5771273. doi: 10.1093.
     PubMed     Abstract available
     
     
     
237. MESSERLI FH, Bangalore S, Messerli AW, Raber L, et al
     The muddy waters of the J-curve and coronary revascularization.
     Eur Heart J. 2020 Mar 2. pii: 5771269. doi: 10.1093.
     PubMed    
     
     
     February 2020
238. JAMALYAN S
     Surgical obesity treatment and the risk of heart failure: the possible mechanisms of interaction and diagnostic accuracy.
     Eur Heart J. 2020 Feb 24. pii: 5753975. doi: 10.1093.
     PubMed    
     
     
     
239. AZAR RR, Abdelmassih T
     Innovation in Heart Failure: from Pills to Devices.
     Eur Heart J. 2020;41:906-907.
     PubMed    
     
     
     
240. VAN WOERDEN G, van Veldhuisen SL, Rienstra M
     Incident heart failure risk after bariatric surgery: the role of epicardial fat.
     Eur Heart J. 2020 Feb 20. pii: 5741377. doi: 10.1093.
     PubMed    
     
     
     January 2020
241. ZHOU Y, Wen J, Nie J
     How much can acute heart failure patients with low basic blood pressure (systolic blood pressure 90-100 mmHg) benefit from the use of vasodilators?
     Eur Heart J. 2020 Jan 10. pii: 5700445. doi: 10.1093.
     PubMed    
     
     
     
242. CLELAND JGF, Lyon AR, McDonagh T, McMurray JJV, et al
     The year in cardiology: heart failure.
     Eur Heart J. 2020 Jan 6. pii: 5694316. doi: 10.1093.
     PubMed    
     
     
     
243. MCMURRAY JJV, Solomon SD, Docherty KF, Jhund PS, et al
     The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context.
     Eur Heart J. 2020 Jan 3. pii: 5695523. doi: 10.1093.
     PubMed    
     
     
     December 2019
244. COHEN-SOLAL A
     Iron deficiency in heart failure: why so frequent and which mechanisms?
     Eur Heart J. 2019 Dec 20. pii: 5682455. doi: 10.1093.
     PubMed    
     
     
     
245. MALMBORG M, Schmiegelow MDS, Norgaard CH, Munch A, et al
     Does type 2 diabetes confer higher relative rates of cardiovascular events in women compared with men?
     Eur Heart J. 2019 Dec 20. pii: 5682397. doi: 10.1093.
     PubMed     Abstract available
     
     
     
246. SCHOU M, Kober L
     Sudden death in heart failure: do we understand what we observe?
     Eur Heart J. 2019 Dec 10. pii: 5671749. doi: 10.1093.
     PubMed    
     
     
     
247. LAM CSP, Arnott C, Beale AL, Chandramouli C, et al
     Sex differences in heart failure.
     Eur Heart J. 2019 Dec 4. pii: 5652224. doi: 10.1093.
     PubMed     Abstract available
     
     
     November 2019
248. BARRA S, Providencia R, Narayanan K, Boveda S, et al
     Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review.
     Eur Heart J. 2019 Nov 21. pii: 5637310. doi: 10.1093.
     PubMed     Abstract available
     
     
     
249. LUSCHER TF
     Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes.
     Eur Heart J. 2019;40:3579-3582.
     PubMed    
     
     
     
250. GOLDENBERG I, Huang DT, Nielsen JC
     The role of implantable cardioverter-defibrillators and sudden cardiac death prevention: indications, device selection, and outcome.
     Eur Heart J. 2019 Nov 12. pii: 5622905. doi: 10.1093.
     PubMed     Abstract available
     
     
     
251. OMLAND T
     Targeting the endothelin system: a step towards a precision medicine approach in heart failure with preserved ejection fraction?
     Eur Heart J. 2019 Nov 4. pii: 5612120. doi: 10.1093.
     PubMed    
     
     
     October 2019
252. NG ACT, Bax JJ
     Hyperdynamic left ventricular function and the prognostic implications for heart failure with preserved ejection fraction.
     Eur Heart J. 2019 Oct 25. pii: 5607286. doi: 10.1093.
     PubMed    
     
     
     
253. HONARBAKHSH S, Prabhu S, Hunter RJ
     With our powers combined: Does the pooled analysis of existing randomized data regarding treatment of atrial fibrillation in heart failure settle the case for catheter ablation?
     Eur Heart J. 2019 Oct 22. pii: 5602553. doi: 10.1093.
     PubMed    
     
     
     
254. REDDY YNV, Obokata M, Wiley B, Koepp KE, et al
     The haemodynamic basis of lung congestion during exercise in heart failure with preserved ejection fraction.
     Eur Heart J. 2019 Oct 14. pii: 5586988. doi: 10.1093.
     PubMed     Abstract available
     
     
     
255. RICHTER S, Di Biase L, Hindricks G
     Atrial fibrillation ablation in heart failure: it's not all about Starling my darling.
     Eur Heart J. 2019 Oct 3. pii: 5580540. doi: 10.1093.
     PubMed    
     
     
     September 2019
256. FELKER GM
     Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure.
     Eur Heart J. 2019 Sep 27. pii: 5575243. doi: 10.1093.
     PubMed    
     
     
     
257. CHATHA SR, Westwood M, Moon JC, Captur G, et al
     New-onset heart failure: free-breathing motion-corrected late gadolinium enhancement rescues the endomyocardial fibrosis diagnosis.
     Eur Heart J. 2019 Sep 27. pii: 5575240. doi: 10.1093.
     PubMed    
     
     
     
258. VAN DER WAL HH, Grote Beverborg N, Dickstein K, Anker SD, et al
     Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.
     Eur Heart J. 2019 Sep 26. pii: 5574384. doi: 10.1093.
     PubMed     Abstract available
     
     
     
259. WIJTVLIET EPJP, Tieleman RG, van Gelder IC, Pluymaekers NAHA, et al
     Nurse-led vs. usual-care for atrial fibrillation.
     Eur Heart J. 2019 Sep 23. pii: 5572602. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2019
260. MCINTYRE WF, Connolly SJ, Wang J, Masiero S, et al
     Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials.
     Eur Heart J. 2019 Aug 4. pii: 5543556. doi: 10.1093.
     PubMed     Abstract available
     
     
     June 2019
261. GENTILLE LORENTE DI
     Coconut atrium: a rare entity to cause pulmonary hypertension.
     Eur Heart J. 2019 Jun 4. pii: 5510776. doi: 10.1093.
     PubMed    
     
     
     January 2019
262. WOJAKOWSKI W, Baumgartner H
     The year in cardiology 2018: valvular heart disease.
     Eur Heart J. 2019 Jan 2. pii: 5265301. doi: 10.1093.
     PubMed    
     
     
     
263. CHAO TF, Lip GYH, Lin YJ, Chang SL, et al
     Age threshold for the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation: insights into the optimal assessment of age and incident comorbidities.
     Eur Heart J. 2019 Jan 2. pii: 5272355. doi: 10.1093.
     PubMed     Abstract available
     
     
     October 2018
264. PETROVIC J, Boricic I, Petrovic M, Ivanovic B, et al
     Endomyocardial fibrosis and unileaflet mitral valve: a fatal postpartum outcome.
     Eur Heart J. 2018 Oct 17. pii: 5137115. doi: 10.1093.
     PubMed    
     
     
     September 2018
265. SZUMMER K, Wallentin L, Lindhagen L, Alfredsson J, et al
     Relations between implementation of new treatments and improved outcomes in patients with non-ST-elevation myocardial infarction during the last 20 years: experiences from SWEDEHEART registry 1995 to 2014.
     Eur Heart J. 2018 Sep 19. pii: 5103432. doi: 10.1093.
     PubMed     Abstract available
     
     
     August 2018
266. POLOVINA M, Hindricks G, Maggioni A, Piepoli M, et al
     Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrial fibrillation.
     Eur Heart J. 2018 Aug 7. pii: 5067645. doi: 10.1093.
     PubMed     Abstract available
     
     
     July 2018
267. TOPILSKY Y, Inojosa JM, Benfari G, Vaturi O, et al
     Clinical presentation and outcome of tricuspid regurgitation in patients with systolic dysfunction.
     Eur Heart J. 2018 Jul 27. pii: 5060565. doi: 10.1093.
     PubMed     Abstract available
     
     
     February 2018
268. YAMAMOTO M, Seo Y, Ishizu T, Aonuma K, et al
     Reversible aortic valve stenosis with Loffler endocarditis.
     Eur Heart J. 2018 Feb 26. pii: 4911114. doi: 10.1093.
     PubMed    
     
     
     
269. RIENSTRA M, Hobbelt AH, Alings M, Tijssen JGP, et al
     Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial.
     Eur Heart J. 2018 Feb 1. pii: 4786620. doi: 10.1093.
     PubMed     Abstract available
     
     
     January 2018
270. MEHLUM MH, Liestol K, Kjeldsen SE, Julius S, et al
     Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
     Eur Heart J. 2018 Jan 20. pii: 4815726. doi: 10.1093.
     PubMed     Abstract available
     
     
     December 2017
271. BERMEJO J, Yotti R, Garcia-Orta R, Sanchez-Fernandez PL, et al
     Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial.
     Eur Heart J. 2017 Dec 21. pii: 4769387. doi: 10.1093.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: